14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.87 $1.65 Wednesday, 24th Apr 2024 ADAP stock ended at $1.08. This is 5.26% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 7.48% from a day low at $1.07 to a day high of $1.15.
90 days $0.691 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
Jan 05, 2024 $0.81 $0.93 $0.80 $0.88 1 513 901
Jan 04, 2024 $0.760 $0.85 $0.750 $0.81 1 394 854
Jan 03, 2024 $0.760 $0.760 $0.690 $0.722 503 766
Jan 02, 2024 $0.81 $0.85 $0.731 $0.746 805 746
Dec 29, 2023 $0.689 $0.84 $0.689 $0.793 1 282 072
Dec 28, 2023 $0.759 $0.759 $0.620 $0.690 1 348 011
Dec 27, 2023 $0.590 $0.724 $0.590 $0.719 1 641 869
Dec 26, 2023 $0.504 $0.620 $0.501 $0.584 1 493 859
Dec 22, 2023 $0.480 $0.502 $0.473 $0.500 695 518
Dec 21, 2023 $0.440 $0.473 $0.430 $0.473 754 937
Dec 20, 2023 $0.460 $0.497 $0.440 $0.441 770 651
Dec 19, 2023 $0.446 $0.495 $0.435 $0.460 1 080 108
Dec 18, 2023 $0.458 $0.460 $0.432 $0.450 1 139 498
Dec 15, 2023 $0.481 $0.497 $0.450 $0.450 1 512 668
Dec 14, 2023 $0.490 $0.514 $0.482 $0.488 548 472
Dec 13, 2023 $0.500 $0.510 $0.482 $0.509 391 831
Dec 12, 2023 $0.500 $0.528 $0.491 $0.495 341 046
Dec 11, 2023 $0.522 $0.530 $0.495 $0.503 426 793
Dec 08, 2023 $0.532 $0.561 $0.530 $0.545 263 091
Dec 07, 2023 $0.580 $0.580 $0.525 $0.570 336 074
Dec 06, 2023 $0.568 $0.589 $0.555 $0.562 769 095
Dec 05, 2023 $0.557 $0.600 $0.500 $0.561 760 576
Dec 04, 2023 $0.530 $0.598 $0.490 $0.529 613 328
Dec 01, 2023 $0.471 $0.548 $0.471 $0.542 333 805
Nov 30, 2023 $0.490 $0.516 $0.471 $0.500 220 154
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT